44.56

1.60% 0.70

After Hours: 44.56

Celldex Therapeutics Inc (CLDX)

Overview News Price History Option Chain Financials Discussions Forecast Stock Split

Celldex Therapeutics Inc stock is traded at $44.56, with a volume of 1.04M. It is up +1.60% in the last 24 hours and up +23.40% over the past month. Celldex Therapeutics Inc is a biopharmaceutical company. It is focused on the development and commercialization of several immunotherapy technologies and other cancer-targeting biologics. The company is also engaged in clinical trials for products targeting breast cancer, metastatic melanoma, lung cancer, solid tumors, and ovarian cancer. Its pipeline products are Varlilumab, CDX-301, CDX-1140,CDX-0159/Anti-KIT Program, and CDX-527.

Previous Close:

$43.86

Open:

$44.89

24h Volume:

1.04M

Market Cap:

$2.94B

Revenue:

$6.07M

Net Income/Loss:

$-144.88M

P/E Ratio:

-16.88

EPS:

-2.64

Net Cash Flow:

$-120.94M

1W Performance:

+21.22%

1M Performance:

+23.40%

6M Performance:

+21.85%

1Y Performance:

+24.26%

1D Range:

$43.10

$46.86

52W Range:

$22.11

$53.18

Celldex Therapeutics Inc Stock (CLDX) Company Profile

Name

Celldex Therapeutics Inc

Sector

Healthcare (1186)

Industry

Biotechnology (681)

Phone

908-200-7500

Address

53 FRONTAGE ROAD, HAMPTON

Employee

160

Twitter

@search?q=celldex

Next Earnings Date

2024-08-06

Latest SEC Filings

CLDX's Discussions on Twitter

Celldex Therapeutics Inc Stock (CLDX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Dec-20-23	Initiated	TD Cowen	Outperform
Nov-10-23	Upgrade	Wells Fargo	Underweight → Equal Weight
Aug-22-23	Initiated	Wells Fargo	Underweight
Sep-17-21	Initiated	Jefferies	Buy
Sep-10-21	Initiated	SVB Leerink	Outperform
Jul-22-21	Initiated	Guggenheim	Buy
Feb-21-20	Initiated	Cantor Fitzgerald	Overweight
Aug-01-17	Resumed	H.C. Wainwright	Buy
Nov-07-16	Initiated	Aegis Capital	Buy
Mar-08-16	Downgrade	Jefferies	Buy → Hold
Mar-07-16	Downgrade	Guggenheim	Buy → Neutral
Mar-07-16	Downgrade	Leerink Partners	Outperform → Mkt Perform
Mar-07-16	Downgrade	Wedbush	Outperform → Neutral
Mar-01-16	Initiated	H.C. Wainwright	Buy
Aug-11-15	Reiterated	Brean Capital	Buy
Aug-11-15	Reiterated	Oppenheimer	Outperform
Aug-11-15	Reiterated	ROTH Capital	Buy
Jun-02-15	Reiterated	WBB Securities	Strong Buy
Nov-17-14	Reiterated	ROTH Capital	Buy
Mar-04-14	Reiterated	Oppenheimer	Outperform
Jul-08-13	Reiterated	Cantor Fitzgerald	Buy
Mar-08-13	Reiterated	Cantor Fitzgerald	Buy
Feb-26-13	Reiterated	Oppenheimer	Outperform
Jan-10-13	Reiterated	Cantor Fitzgerald	Buy
Oct-02-12	Reiterated	Oppenheimer	Outperform
Sep-14-12	Reiterated	Cantor Fitzgerald	Buy